Conceptus, Inc. (NASDAQ:CPTS) will participate in the OneMedPlace Finance Forum on Tuesday, January 12. The conference will be held at the Sir Francis Drake Hotel in San Francisco. Representing Conceptus will be President and Chief Executive Officer Mark Sieczkarek.
MicroCap Insider is a web-based financial portal.
Sign Up for our Free Stock Newsletter
MicroCap Insider publishes a free penny stock newsletter providing stock alerts on companies positioned to deliver high-yield gains to investors.
Mr. Sieczkarek will begin his presentation at 2:15 pm PT that afternoon. Those unable to attend the event may listen to a webcast on the company’s website, http://www.conceptus.com/. The webcast will remain on the site for instant replay for thirty days following the end of the event.
Conceptus, Inc. develops, manufactures and markets the Essure permanent birth control system, a medical device for women that is approved for marketing in the United States by the United States Food and Drug Administration (FDA). The Essure system uses a soft and flexible micro-insert that is delivered into a woman's fallopian tubes to provide permanent birth control by causing benign tissue in-growth that blocks the fallopian tubes. A properly placed Essure micro-insert and the subsequent tissue growth prohibits the egg from traveling through the fallopian tubes and therefore prevents fertilization. On January 7, 2008, the Company acquired all of the outstanding shares of Conceptus SAS. Through Conceptus SAS, it sells Essure directly in France and uses distributors to sell Essure throughout the rest of Europe.
Sign Up for FREE. Investors interested in receiving small cap stock alerts through the penny stock newsletter published by MicroCap Insider can sign up for free by visiting our website.
About Us
MicroCap Insider is a leading penny stock web site with extensive experience in the OTC market, providing top stock picks, investing tips and exclusive research on small cap stocks on the verge of producing large financial gains.
Please click here to read the full disclaimer.
